This week’s bulletin (which is coming a few days later than our usual Friday communiqué) offers a deep dive into COMPASS Pathways’ topline Phase 2b results, which were released last Tuesday. In this long-read piece we seek to begin contextualising the preliminary safety and efficacy data from this influential trial, and end by summarising the next steps for COMPASS. Topline results from COMPASS…


Previous articleMindset Pharma Announces Poster Presentation of Preclinical Data for Benchmarking Next-Generation Psychedelics at Neuroscience 2021
Next articleRed Light Holland Psilocybin Truffles, Sold in The Netherlands, Complete First Evaluation Under a Health Canada Approved cGMP Laboratory